WADD - IL PROGRAMMA

2nd World Congress of

World Association on Dual Disorders

Dual Disorders: Towards a New Paradigm in Neuroscience to Understand Mental Health 25-27 October 2018 Convitto della Calza Florence, Italy, EU

WADD

World Association on Dual Disorder WADD was founded in Barcelona (Spain) in April 2015. It shall remain independent of political parties and of any government.

The vision

The World Association of Dual Disorders (WADD) was created to • Increase the level of knowledge and education on Dual Disorders • Create a live tool which can serve as the major point of reference and contact to Dual Disorders related professionals.

• Increase the awareness of Dual Disorders worldwide and offer a platform for all Dual Disorder professionals.

• Promote the research on Dual Disorders.

• Promote the dissemination of information on Dual Disorders among health professionals, government and the public at large.

• Give voice to and represent professionals in the Dual Disorder area by providing information and scientific knowledge.

• Reduce the stigma related to Dual Disorders

WADD Executive Committee Pedro Ruiz (Houston, TX, USA) - President Miguel Casas (Barcelona, Spain, EU) - Vice President Nestor Szerman (Madrid, Spain, EU) - Executive Secretary Icro Maremmani (Pisa, Italy, EU) - Treasurer

WADD-Italia Scientific Committee Giampaolo Spinnato (Palermo, Italy, EU) - President Icro Maremmani (Pisa, Italy, EU) - Scientific Director Vinicio Claudio Romano (Piazza Armerina, Italy, EU) - Member Riccardo Gionfriddo (Siracusa, Italy, EU) - Member Francesco Lamanna (Pisa, Italy, EU) - Member

Under the Patronage of WADD - World Association on Dual Disorder WADD-Italia Scientific Committee Promoted by WADD-Italia Scientific Committee Association for the Application of Neuroscientific Knowledge to Social Aims Congress Presidents PEDRO RUIZ (Houston, TX, USA) ICRO MAREMMANI (Pisa, Italy, EU) Local Scientific Committee GIULIO PERUGI (Pisa, Italy, EU) GIAMPAOLO SPINNATO (Palermo, Italy, EU)

Venue Convitto della Calza Piazza della Calza, 6 50125 Florence FI Phone: +39 055 22228 E-mail: CALZA@CALZA.IT Website: https://www.calza.it/en

Organizing Committee Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy Phone +39 0564412038 - Fax +39 0564412485 E-mail: giusi@tigicongress.com Helping people to understand neuroscientific update

AU-CNS

Association for the Application of Neuroscientific Knowledge to Social Aims

AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, Italy Phone +39 0584790073 - Fax +39 058472081 E-mail:info@aucns.org

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

PROGRAM THURSDAY, OCTOBER 25, 2018 WADD SELECTED ORAL PRESENTATIONS Plenary Room

ABSTRACT No

8:20

SOP-1

DANIEL FEINGOLD (Ariel, Israel) - Clinical and functional outcomes of cannabis use among individuals with depression and anxiety: a three-year population-based longitudinal study

8:40

SOP-2

NADIR BOURBON (Blida, Algeria) - Opiate addiction and others psychiatric diagnosis

9:00

SOP-3

EMANUELA ATZORI (Roma, Italy, EU) - The alteration of the sensory consciousness of the SELF as a trigger mechanism determining a craving in gambling and eating disorders. A pilot study

9:20

SOP-4

LEE KUN-HUA (Hsinchu, Taiwan) - The training and recruits of mindfulness-based relapse prevention therapist in Taiwan: a descriptive study

9:40

SOP-5

SHAUL LEV-RAN (Netanya, Israel) - Comparing substance misuse, anxiety and depression among individuals with chronic pain receiving prescription opioids and medical marijuana

10:00

SOP-6

FRANCINA FONSECA (Barcelona, Spain, EU) - Personality traits, psychiatric comorbidity and methadone maintenance treatment outcome

10:20

SOP-7

MYRIAM PAPERMAN (Paris, France, EU) - Borderline Personality Disorder and Substance Use Disorder: A life worth living?

WADD Selected Presentations Chair: Matteo Pacini (Pisa, Italy, EU)

10:40

WADD General Assembly

11:40

SPECIAL EVENT in collaboration with Industry

13:00

LUNCH BREAK

Florence, Italy, October 25-27, 2018

-4-

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

THURSDAY, OCTOBER 25, 2018 Plenary Room

ABSTRACT No

OPENING CEREMONY

PEDRO RUIZ (Houston, TX, USA) MIGUEL CASAS (Barcelona, Spain, EU) NESTOR SZERMAN (Madrid, Spain, EU) ICRO MAREMMANI (Pisa, Italy, EU)

13:20

PLENARY LECTURES

Chair: Icro Maremmani (Pisa, Italy, EU)

Miguel Casas (Barcelona, Spain, EU) 13:30

PL-1

PEDRO RUIZ (Houston, TX, USA) - Focus on Dual Disorder

14:30

PL-2

MICHAEL KRAUSZ (Vancouver, BC, Canada) - Homeless and hopeless – marginalized urban with complex concurrent disorders and the North American overdose crisis

PARALLEL SYMPOSIA 1- SOUTH EASTERN EUROPEAN ADDICTION TREATMENT NETWORK (SEEANET) SYMPOSIUM- PART 1 Chair: Andrej Kastelic (Ljubljana, Slovenia, EU)

Plenary Room

ABSTRACT No

15:30

S01-1

LILJLANA IGNJATOVA (Skopje, North Macedonia) - Differences and similarities in opioid use and bipolar disorders

16:00

S01-1

NUSA SEGREC (Ljubljana, Slovenia, EU) - Sexual disfunction among men in agonist opioid treatment

16:30

S01-1

JELEANA RISTIC-ILIC (Ljubljana, Slovenia, EU) - Personality disorders and substance abuse 2- IMPROVING TREATMENT OUTCOMES IN DUAL DISORDER PATIENTS: AN OVERVIEW OF NEW PSYCHOLOGICAL AND BEHAVIOURAL INTERVENTIONS IN CLINICAL PRACTICE Chair: Tony Bloemendaal (Den Haag, Nederland, EU)

Room A 15:30

S02-1

ANNETTE BONEBAKKER (Den Haag, Netherlands, EU) - New perspectives on the treatment of duals disorders: integrative care and psychological treatments

16:00

S02-2

ERNST NOORDRAVEN (Den Haag, Netherlands, EU) - Money for medication: financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders; a randomised controlled trial

16:30

S02-3

TONY BLOEMENDAAL (Den Haag, Netherlands, EU) - Treatment no-response in patients with a dual disorder 3-DUAL DISORDER PATIENTS IN COMMUNITY MENTAL HEALTH SERVICES Chair: Celia Franco (Coimbra, Portugal, EU)

Room B 15:30

S03-1

TANIA SILVA (Coimbra, Portugal, EU) - Dual disorder patient in community mental health services: the experience of the centre of Portugal

16:00

S03-2

FILOMENA NETO (Coimbra, Portugal, EU) - Dual disorder patient: multidisciplinary team intervention in community mental health services

16:30

S03-3

CELIA FRANCO (Coimbra, Portugal, EU) - Treating addiction patients in community mental health services: the role of opioid treatment

PLENARY LECTURE

Chair: Gabriele Fischer (Vienna, Austria, EU)

Arturo Lerner (Tel Aviv, Israel) 18:00

PL-3

NESTOR SZERMAN (Madrid, Spain, EU) - Precision Medicine in Dual Disorders

19:00

PL-4

MIGUEL CASAS (Barcelona, Spain, EU) - Cocaine Addiction: a self-medication hypothesis. A systematic review

20:00

Welcome Cocktail and Luca Rovai Research Award

Florence, Italy, October 25-27, 2018

-5-

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Plenary Room

Florence, Italy, October 25-27, 2018

Disorders|Congress

ABSTRACT No

FRIDAY, OCTOBER 26, 2018 PARALLEL SYMPOSIA 4 - DUAL DISORDERS TREATMENT Chair: Vera Martins (Coimbra, Portugal, EU) 9:00

S04-1

CELIA FRANCO (Coimbra, Portugal, EU) - Treatment phases in dual patients

9:30

S04-2

ELISABETE ALBUQUERQUE (Coimbra, Portugal, EU) - Opioid treatment: a new way to understand addiction

10:00

S04-3

VERA MARTINS (Coimbra, Portugal, EU) - The role of treatment in day hospital in dual disorders patients 5- ARE BENZODIAZEPINES THE CURE FOR OR THE CAUSE OF PROBLEMS? THE ROLE OF BENZODIAZEPINES IN TREATMENT AND OUTCOMES OF OPIOID ADDICTION Chair: Thomas Clausen (Oslo, Norway)

Room A 9:00

S05-1

LARS TANUM (Oslo, Norway) - Use of benzodiazepines among opioid dependent individuals during a 12 week randomised study and a 36-week follow-up study with extended release naltrexone

9:30

S05-2

ASHLEY MULLER (Oslo, Norway) - Long-term opioid maintenance treatment patients and the role of benzodiazepines

10:00

S05-3

THOMAS CLAUSEN (Oslo, Norway) - Unprescribed benzodiazepine use predicts oneyear instability in opioid maintenance treatment 6- OUTCOME OF PATIENTS WITH DUAL DIAGNOSIS - EXPERIENCE OF 25 YEARS IN METHADONE MAINTENANCE TREATMENT CLINIC Chair: Einat Peles (Tel Aviv, Israel)

Room B 9:00

S06-1

EINAT PELES (Tel Aviv, Israel) - Predictors for schizophrenia and psychotic patients outcome in methadone maintenance treatment

9:30

S06-2

ANAT SASON (Tel Aviv, Israel) - Depression, food addiction, weight gain and nutrition habit among patients in methadone maintenance treatment

10:00

S06-3

SHAUL SCHREIBER (Tel Aviv, Israel) - The relation between brief psychiatric rating scale (BPRS) on admission to methadone maintenance treatment and treatment outcome BREAK

10:30

PLENARY LECTURES

Chair: Giulio Perugi (Pisa, Italy, EU)

Nestor Szerman (Madrid, Spain, EU) 11:00

PL-5

MARIO MAJ (Naple, Italy, EU) - Aetiopathogenetic and Therapeutic Complexity of Schizophrenia

12:00

PL-6

ICRO MAREMMANI (Pisa, Italy) - Clinical foundation for the use of Agonist Opioid Medications in Bipolar Disorder and Psychosis

13:15

LUNCH BREAK

Florence, Italy, October 25-27, 2018

-6-

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Plenary Room

Florence, Italy, October 25-27, 2018

Disorders|Congress

ABSTRACT No

PLENARY LECTURES

Chair: Icro Maremmani (Pisa, Italy, EU)

Christian Schutz (Vancouver, Canada)

14:30

PL-7

GIULIO PERUGI (Pisa, Italy, EU) - Aetiopathogenetic and Therapeutic Complexity of Bipolar Disorders

15:30

PL-8

MARTA TORRENS (Barcelona, Spain, EU) - Opioid and depression

PARALLEL SYMPOSIA 7- SUBSTANCE USE DISORDERS AND PSYCHIATRIC COMORBIDITIES: WHICH TREATMENT OPTIONS DO WE HAVE? Chair: Marta Torrens (Barcelona, Spain, EU)

Plenary Room

ABSTRACT No

16:30

S07-1

ANGELO G. I. MAREMMANI (Viareggio, Italy, EU) - Substance abuse and psychosis: the strange case of opioids

17:00

S07-2

CARLO IGNAZIO CATTANEO (Borgonero, Italy, EU) - The phenomenon of drug resistance in substance induced psychosis

17:30

S07-3

CORRADO MANNI (Pisa, Italy, EU) - Cocaine use disorder in ADHD individuals: focus on comorbidities and treatments outcome 8- DUAL DISORDERS IN MEXICO Chair: Carmen Fernandez Caceres (Mexico City, Mexico)

Room A 16:30

S08-1

CARMEN FERNANDEZ CACERES (Mexico City, Mexico) - Dual disorders in drug users served in a network of specialized addiction care

17:00

S08-2

ANGEL PRADO GARCIA (Mexico City, Mexico) - From prevention to rehabilitation, a continuum under the dual pathology model

17:30

S08-3

ANDREA GALLEGOS-CARI (Mexico City, Mexico) - Electronic screening tool for dual disorders in residential facilities to treat SUDs in Mexico City 9-COMORBIDITY AND SEXUALLY TRANSMITTED INFECTIONS – LONGITUDINAL EVIDENCE, TREATMENT SEEKING AND TREATMENT OPPORTUNITIES Chair: Rosa Alati (Brisbane, Australia)

Room B 16:30

S09-1

ROSA ALATI (Brisbane, Australia) - Generational changes in substance use – cross country comparisons

17:00

S09-2

CAROLINE SALOM (Brisbane, Australia) - Longitudinal links between comorbidity, treatment-seeking and sexually transmitted infections – opportunities for screening and treatment

17:30

S09-3

RODRIGO MARIN-NAVARRETE (Mexico City, Mexico) - Development of an evidencebased model of rapid testing and counselling for HIV and other ITDs for addiction treatment centres in Mexico

PLENARY LECTURES

Chair: Michael Krausz (Vancouver, BC, Canada)

Yifrah Kaminer (Hartford, CT, USA)

18:00

PL-9

CHRISTIAN G. SCHÜTZ (Vancouver, Canada) - Disentangling dual diagnosis: focus on stimulants and psychotic disorders

Florence, Italy, October 25-27, 2018

-7-

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Plenary Room

Florence, Italy, October 25-27, 2018

Disorders|Congress

ABSTRACT No

SATURDAY, OCTOBER 27, 2018 PARALLEL SYMPOSIA 10 - SOUTH EASTERN EUROPEAN ADDICTION TREATMENT NETWORK (SEEANET) SYMPOSIUM- PART 2 Chair: Andrej Kastelic (Ljubljana, Slovenia, EU) 9:00

S10-1

MIRJANA DELIC (Ljubljana, Slovenia, EU) - Use of psychedelics and antagonists in psychiatric treatment: pros and cons

9:30

S10-2

TATJA KOSTNAPFEL (Ljubljana, Slovenia, EU) - Outpatient prescription of antidepressants and anxiolitics in Slovenia

10:00

S10-3

MARJETKA JELENC (Ljubljana, Slovenia, EU) - Zolpidem use in elderly patients in Slovenia 11- PSYCHO-ADDICTOLOGY: FROM CONCEPTUALIZATION TO APPLICATION Chair: Amine Benyamina (Paris, France, EU)

Room A 9:00

S11-1

DANIELE ZULLINO (Geneve, Switzerland) - The institutionalization of psychoaddictology in Switzerland: the federal diploma of advanced training

9:30

S11-2

GEORGES BROUSSE (Clermont Ferrand, France, EU) - The dimensional approach in the service of psycho-addictology: the example of impulsivity

10:00

S11-3

ISMAIL RAMMOUZ (Agadir, Morocco) - Towards a psychopharmacology with dual action?

12- HOT TOPICS IN DUAL DISORDERS Chair: Roger D. Weiss (Boston, MA, USA)

Room B 9:00

S12-1

ALBRECHT ULMER (Stuttgard, Germany, EU) - Medical adjustment of alcohol dependence with baclofen, dihydrocodeine, buprenorphine, clomethiazole and possible other substances

9:30

S12-2

MATTEO PACINI (Pisa, Italy, EU) - Benzodiazepine abuse in a private outpatient treatment setting - psychiatric common grounds and typization of BDZ-bound addictive behaviour

10:00

S12-3

ROGER D. WEISS (Boston, MA, USA) - Opioid use disorder, depression, chronic pain, overdose, and suicidality: how are they related?

BREAK

PLENARY LECTURES

Chair: José MARTINEZ-RAGA (Valencia, Spain, EU)

Carlos Roncero (Salamanca, Spain, EU) 11:00

PL-10

YIFRAH KAMINER (Farmington, CT, USA) - Challenges for the Treatment of Cooccurring Depression in Youth with SUD: Highs and Lows

12:00

PL-11

DANIELE LA BARBERA (Palermo, Italy) - Behavioural Addictions and Dual Disorders

13:15

LUNCH BREAK

Florence, Italy, October 25-27, 2018

-8-

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Plenary Room

Florence, Italy, October 25-27, 2018

Disorders|Congress

ABSTRACT No

PLENARY LECTURES

Chair: Lorenzo Somaini (Biella, Italy, EU)

Maurice Dematteis (Grenoble, France, EU)

14:30

PL-12

JOSÈ MARTINEZ-RAGA (Valencia, Spain) - Causality or casuality. ADHD and substance use disorders

15:30

PL-13

GABRIELE FISCHER (Vienna, Austria) - Prisoners with substance use disorder and other comorbidities – medical and human rights considerations

PARALLEL SYMPOSIA 13- NOVEL PSYCHOACTIVE SUBSTANCES: PSYCHIATRIC CONSEQUENCES AND RELATED BEHAVIOURAL ADDICTIONS IN DUAL DIAGNOSED PATIENTS Chair: Rok Tavcar (Ljubljana, Slovenia, EU)

Plenary Room

ABSTRACT No

16:30

S13-1

MOJCA ZVEZDANA DERNOVSEK (Ljubljana, Slovenia, EU) - Novel psychoactive substances use: challenges in assessing, diagnostic, treatment and clinical management in young forensic patients

17:00

S13-2

MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Novel psychoactive synthetic cannabinoids and cathinones use: challenges in assessing, diagnostic, treatment and clinical management in dual disorders

17:30

S13-3

ROK TAVCAR (Ljubljana, Slovenia, EU) - Novel psychoactive substances use: challenges in assessing, diagnostic, treatment and clinical management of patients with schizophrenia 14- ARE WE ABLE TO DEVELOP APPROPRIATE DUAL DISORDERS TREATMENT RESOURCES?: BARRIERS AND FACILITATORS Chair: Lola Peris (Neuchatel, Switzerland)

Room A 16:30

S14-1

CELIA FRANCO (Coimbra, Portugal, EU) - Is the road to develop dual disorders treatment programs and resources long and winding?

17:00

S14-2

LARS LIEN (Oslo, Norway) - Do we know how to advance in the development of dual disorders treatment programs and resources?

17:30

S14-3

LOLA PERIS (Neuchatel, Switzerland) - Are dual disorders integrated treatment programs and resources a realistic issue today?

15-TOWARD A PSYCHOPATHOLOGY SPECIFIC TO SUDS. AN UP TO DATE Chair: Angelo G.I. Maremmani (Viareggio, Italy, EU)

Room B 16:30

S15-1

IACOPO BELCARI (Pisa, Italy, EU) - Personality traits and aggressive behaviour of Dual Disorder Patients

17:00

S15-2

ICRO MAREMMANI (Pisa, Italy, EU) - Affective temperaments as preexisting addiction factors

17:30

S15-3

ANGELO G.I. MAREMMANI (Viareggio, Italy, EU) - Toward a psychopathology specific to SUDs. An up to date

PLENARY LECTURES

Chair: Icro Maremmani (Pisa, Italy, EU)

Pedro Ruiz (Houston, TX, USA) 18:00 19:00

PL-14

ARTURO G. LERNER (Netanya, Israel) - Hallucinogen persisting perception disorders: The story of “dragons, fairies and giants” or “witches do certainly exist” or “the never ending trip” CLOSING CEREMONY

Florence, Italy, October 25-27, 2018

-9-

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

POSTER SESSION PO-1. A. Adan et al. (Barcelona, Spain, EU) - Circadian Rhythms In Substance Use Disorders With And Without Depression PO-2. A. Adan et al. (Barcelona, Spain, EU) - Neuropsychological profile of dual depressed patients PO-3. T. Aladashvili (Tbilisi, Georgia) - Borderline personality disorder and comorbid addiction PO-4. E. Albuquerque and T. Carvalhão (Coimbra, Portugal, EU) - Multiple sclerosis and cognitive decline, presenting with alcohol abuse and compulsive buying: A case report PO-5. E. Atzori et al. (Roma, Italy, EU) - Evidence-based prevention of substance abuse in high school adolescents. The change of a perspective to protect and at the same time combat a stigma PO-6. O. Austin and P. Rosca (Jerusalem, Israel) - Culture sensitivity in dual diagnosis services in Israel PO-7. F. C. Blow et al. (Ann Arbor, MI, USA) - High risk drinking and prescription drug misuse: Relationship with suicidal ideation among US national guard soldiers PO-8. M. Caloro et al. (Rome, Italy, EU) - Affective temperament in patients with persistent ADHD and substance use disorder (cocaine) PO-9. T. Carvalhão and E. Albuquerque (Coimbra, Portugal, EU) - Behavioural dependencies: Pathological gambling - structured consultation experience in a central hospital in Portugal PO-10. N. M. Casado-Espada et al. (Salamanca, Spain, EU) - Eating disorders and substance use in a sample of patients in the eating disorders treatment unity of Salamanca, Spain PO-11. G. Catalano et al. (Roma, Italy, EU) - Towards a combined treatment for dual diagnosis PO-12. L. Costantino (Roma, Italy, EU) - Psychopathology and clinic of eating disorders: The defence from depression. An interpretation according to Massimo Fagioli’s “Human birth theory” PO-13. P. Dannon (Tel Aviv, Israel) - Distinct response inhibition patterns in obsessive compulsive disorder patients and pathological gamblers PO-14. J. I. de la Iglesia Larrad et al. (Salamanca, Spain, EU) - Cocaine-induced schizophrenia-like disorder: A case report PO-15. A. Deschenau et al. (Villejuif, France, EU) - Acceptability of the assist questionnaire to assess substance use troubles in a French psychiatric patients’ population PO-16. A. Fiore and E. Vasile (Pordenone, Italy, EU) - Gratification in group psychotherapies of DD patients PO-17. A. Fleischman (Tel Aviv, Israel) - Characteristics of patients with dual-diagnosis in outpatient addiction treatment services in Tel Aviv PO-18. M. Fraga and P. Carriço (Coimbra, Portugal) - Perverse complicities PO-19. A. Franceschini (Treviso, Italy, EU) - Misuse of prescription psychotropic drugs among women: A possible iatrogenic dual disorder?

PO-20. M. Á. García-Carretero et al. (Cadiz, Spain, EU) - The petit scale on schizophrenic population with alcohol use disorder: A pilot study PO-21. A. Garcia-Guix et al. ( Barcelona, Spain, EU) - Clinical profile of patients with dual disorders in an outpatient addiction centre follow up. An observational study PO-22. M. Griffin (Belmont, MA, USA) - Grit in patients with substance use disorder

Florence, Italy, October 25-27, 2018

- 10 -

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

PO-23. B. Haight et al. (Richmond, VA, USA) - RBP-6000 Buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials PO-24. M. Ilgen et al. (Stanford, CA, USA) - Randomised controlled trial of telephone monitoring with psychiatry inpatients with cooccurring substance use and mental health disorders PO-25. M. Jesus et al. (Coimbra, Portugal, EU) - Alcohol consumption in the elderly PO-26. S. Kandrakonda et al. (Hyderabad, India) - Comorbidity of Adult ADHD and TreatmentResistant Depression: Augmentation with Methylphenidate PO-27. A. Kantchelov and V. Parvanov (Sofia, Bulgaria, EU) - Enhancing treatment engagement in addicted patients with depression PO-28. O. Kukhianidze and N. Okribelashvili (Tbilisi, Georgia) - Some issues in dual diagnosis in psychiatry in Georgia PO-29. S. P. Kurtz et al. (Miami, FL, USA) - Brief interventions for young adults who use drugs: ‘The moderating effects of resilience and trauma’ PO-30. M. Lucas et al. ( Albacete, Spain, EU) - The difficulty of the psychopharmacological treatment in dual pathology PO-31. C. Manni et al. (Pisa, Italy, EU) - From intense to occasional use of cocaine in Dual Disorder (Adult Attention Deficit Hyperactive Disorder/Cocaine Use Disorder) patients treated with stimulant medications PO-32. V. Marcinkene and A. Sangarijeva (Riga, Latvia, EU) - Impact of methadone long-term pharmacotherapy program on the results of HIV treatment in Latvia PO-33. J. E. Marquez-Arrico et al. (Barcelona, Spain, EU) - Personality traits of patients with Dual Disorders: A psychobiological approach PO-34. D. Medved et al. (Oslo, Norway) - Disease burden in ageing long-term opioid maintenance treatment patients; the triple burden PO-35. F. Mora Mínguez et al. (Madrid, Spain, EU) - Excessive use of new technologies as a risk factor for eating disorders PO-36. A. Neven (Den Haag, Netherlands) - The efficacy of IDDT on hospitalized dual disorder patients PO-37. A. Neven (Den Haag, Netherlands) - Evaluation of seclusion in patients with severe dual disorders PO-38. L. Oviedo et al. (Barcelona, Spain, EU) - Sociodemographic and clinical characteristics of methamphetamine shabu users in Barcelona PO-39. A. Pallucchini et al. (Pisa, Italy, EU) - Clinical Characteristics of Dual Disorder (Adult ADHD with and without cocaine abuse) patients PO-40. V. Perepjolkina et al. (Riga, Latvia, EU) - Pathological personality traits among patients with alcohol use disorder: Assessment of comorbidity of personality pathology and alcohol dependence PO-41. L. Peris et al. (Neuchâtel, Switzerland) - Early abstinence, exercise and craving: A preliminary study PO-42. R. M. Prado (Madrid, Spain, EU) - “Chemsex”: How and why should we treat this patients in an addiction centre

Florence, Italy, October 25-27, 2018

- 11 -

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

PO-43. G. Prat et al. (Manresa, Spain, EU) - Factors related to brain impairment in dual schizophrenia PO-44. S. Rabinovitz et al. (Haifa, Israel) - Substance use and severe mental health outcomes in sexual assault victims PO-45. I. Ritacco (Roma, Italy, EU) - Alexithymia and benzodiazepine misuse PO-46. M. Robles-Martínez et al. (Barcelona, Spain, ​​ EU) - Cannabis hyperemesis syndrome in a patient with generalized developmental disorder PO-47. M. Robles Martínez et al. (Barcelona, Spain) - Erectile dysfunction secondary to repeated priapism due to chronic consumption of GHB PO-48. P. Rocco (Castelfranco Veneto, Italy, EU) - ADHD in heroin addicts: Prevalence and psychiatric comorbidity PO-49. P. Romero et al. (Albacete, Spain, EU) - Multidisciplinary approach for patients with dual pathology PO-50. P. Rosca et al. (Jerusalem, Israel) - Rehabilitation in dual diagnosis: Filling the gap in the Israeli policy PO-51. A. Ruz Sánchez et al. (Granada, Spain, EU) - A case of psychosis by Ayahuasca PO-52. R. B. Sauras Quetcuti et al. (Barcelona, Spain) - First psychotic episodes in smoked methamphetamine users: Patterns of use and clinical features PO-53. L. Shriki-Tal et al. (Ness-Ziona, Israel) - The new youth dual disorders day care clinic – system in progress PO-54. G. Spinnato et al. (Palermo, Italy, EU) - Towards a nosography of “dual disorder”: Qualitative analysis of some clinical types PO-55. R. G. Stern and J. E. Stern (Staten Island, NY, USA) - Trazodone for insomnia in patients with substance abuse - a critical review PO-56. T. Stoykova (Sofia, Bulgaria, EU) - Addicted patients with personality disorders: Preconditions, challenges and psychotherapeutic mechanisms of change PO-57. C. Tagliarini et al. (Pisa, Italy, EU) - Specific psychopathology of SUDs. Comparison between Italian and migrant patients PO-58. A. Ulmer (Stuttgard, Germany, EU) - Addressing smoking three times a year PO-59. A. Wolf et al. (Ness Ziona, Israel) - The new dual disorders division – system in progress: Past vs future

Florence, Italy, October 25-27, 2018

- 12 -

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

Faculty Ana ADAN

Department of Clinical Psychology and Psychobiology, and Institute of Neurosciences, University of Barcelona, Spain, EU - [E-Mail: aadan@ub.edu]

Tamar ALADASHVILI

Centre for Mental Health and Prevention of Addiction, Tbilisi, Georgia - [E-Mail: aladashvilitamar@yahoo.com]

Rosa ALATI

University of Queensland QLD, Brisbane, Australia - [E-Mail: r.alati@sph.uq.edu. au]

Elisabete ALBUQUERQUE

Coimbra Hospital and University Centre, Coimbra, Portugal, EU - [E-Mail: a.didascalia@gmail.com]

Emanuela ATZORI

Clinical Psychologist, Roma, Italy, EU - [E-Mail: emanuela.atzori@tin.it]

Ofra AUSTIN

Department for the Treatment of Substance Abuse, Ministry of Health, Israel, Jerusalem, Israel - [E-Mail: OFRA.AUSTIN@MOH.GOV.IL]

Iacopo BELCARI

VP Dole Research Group, Institute of Behavioural Sciences (IBS), Pisa, Italy, EU - [E-Mail: iacopo.belcari@gmail.com]

Tony BLOEMENDAAL

Centrum Dubbele Problematiek, Fivoor, Den Haag, Netherlands - [E-Mail: t.bloemendaal@fivoor.nl]

Annette BONEBAKKER

Centrum Dubbele Problematiek, Fivoor, Den Haag, Netherlands, EU - [E-Mail: a.bonebakker@fivoor.nl]

Frederic C BLOW

Addiction Centre, Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA - [E-Mail: fredblow@umich.edu]

Annette BONEBAKKER

Centrum Dubbele Problematiek, Fivoor, Den Haag, Netherlands, EU - [E-Mail: a.bonebakker@fivoor.nl]

Nadir BOURBON

Department Psychiatry-Addiction. Psychiatric Hospital Frantz Fanon. Blida.

Algeria - [E-Mail: n.bourbon@hotmail.com]

George BROUSSE

University Clermont Auvergne, Clermont Ferrand, France, EU - [E-Mail: gbrousse@chu-clermontferrand.fr, h.rahioui@ch-sainte-anne.fr]

Matteo CALORO

NESMOS department, University of Rome Sapienza, Medical School, Sant’Andrea Hospital, Rome, Italy, EU - [E-MAIL: m.caloro@gmail.com]

Teresa CARVALHÃO

Centro Hospitalar e Universitário de Coimbra - Psychiatry Department, Coimbra, Portugal, EU - [E-Mail: tecarvalhaosantos@gmail.com]

Nerea Maria CASADO-ESPADA

Salamanca University Healthcare Complex, - [E-Mail: nmcasado91@gmail.com]

Miguel CASAS

Universitat Autonoma del Barcelona, Spain, EU - [E-Mail: mcasas@vhebron.net]

Gabriella CATALANO

Drug Addiction Unit, USL Roma 1, Roma, Italy, EU - [E-Mail: gabriella.catalano@ aslroma1.it]

Carlo Ignazio CATTANEO

Department of Mental Health Novara, Borgomanero, Italy, EU - [E-Mail: dr.carloignaziocattaneo@gmail.com]

Thomas CLAUSEN

Norwegian Centre for Addiction Research, University of Oslo, Norway - [E-Mail: thomas.clausen@medisin.uio.no]

Ludovica COSTANTINO

Psychiatrist and Psychotherapist, Roma, Italy, EU - [E-Mail: mm8508@mclink.it]

Pinhas DANNON

Tel Aviv University Ness Zionah Mental Health Ctr, Tel Aviv, Israel - [E-Mail: pinhas.danon@moh.gov.il]

Javier Ignacio DE LA IGLESIA LARRAD

Salamanca Healthcare Complex,, Salamanca, Spain, EU - [E-Mail: javidelaiglesia@ hotmail.com]

Mirjana DELIC

Centre for Treatment of Drug Addiction. University Psychiatric Clinic Ljubljana, Slovenia, EU - [E-Mail: mirjanadelic@yahoo.com]

Florence, Italy, October 25-27, 2018

- 13 -

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

Faculty Maurice DEMATTEIS

CHU Grenoble-Alpes, Grenoble, France, EU; INSERM UMR 987, Boulogne Billancourt, France; Hospital Cochin, Paris, France, EU -, Grenoble, France, EU [E-Mail: MDematties@chu-grenoble.fr]

Mojca Zvezdana DERNOVSEK

Medical School University of Ljubljana, Slovenia, EU - [E-MAIL: mojca_ dernovsek@t-2.net]

Alice DESCHENAU

Paul Guiraud Hospital, Villejuif, France, EU - [E-Mail: alice.deschenau@ghpaulguiraud.fr]

Daniel FEINGOLD

Ariel University, Ariel, Israel, - [E-Mail: d.y.feingold@gmail.com]

Carmen FERNANDEZ CACERES

Centros de Integración Juvenil A.C. (CIJ), Mexico City, Mexico, - [E-Mail: cfernandez@cij.gob.mx]

Andrea FIORE

AAS 5 Friuli Occidentale, Pordenone, Italy, EU - [E-Mail: fioreandrea.a@libero.it]

Gabriele FISCHER

Medical School, University of Vienna, Austria, - [E-Mail: gabriele.fischer@ meduniwien.ac.at]

Anat FLEISCHMAN

Yaffo Community Mental Health Centre, Tel Aviv, Israel - [E-Mail: anat. fleischman@gmail.com]

Francina FONSECA

Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain, EU - [E-Mail: mffonseca@parcdesalutmar.cat]

Manuela FRAGA

Equipa de Tratamento de Coimbra do Departamento de Intervenção em Comportamentos Aditivos e Toxicodepência, Coimbra, Portugal - [E-Mail: fraga. manuela@gmail.com]

Anna FRANCESCHINI

Addiction Medicine Clinic, NHS Treviso, Italy, EU - [E-Mail: anna.franceschini@ aulss2.veneto.it]

Celia FRANCO

Coimbra University Hospital, Coimbra, Portugal, EU - [E-Mail: celiacfranco@ gmail.com]

Andrea GALLEGOS-CARI

Institute for attention and prevention of addictions in Mexico City (IAPA), Mexico City, Mexico - [E-Mail: agallegosc@iapa.cdmx.gob.mx]

Miguel Ángel GARCÍACARRETERO

CTS-391 Multidisciplinary Group for the progress of Mental Health, Cadiz University; School of Nursing and Physiotherapy in Cadiz, Spain, EU - [E-Mail: miguel.garcia.carretero@hotmail.com]

Alexandra GARCIA-GUIX

Cas Santa Coloma, Institut de Neuropsiquiatria i addiccions-INAD, Parc de Salut Mar, Barcelona, Spain, EU - [E-Mail: 62755@parcdesalutmar.cat]

Margaret GRIFFIN

McLean Hospital/Harvard Medical School, Boston, MA, USA, Belmont, MA, USA - [E-Mail: mgriffin@mclean.harvard.edu]

Barbara HAIGHT

Indivior Inc., Richmond, VA, USA - [E-Mail: Barbara.R.Haight@gmail.com]

Liljlana IGNJATOVA

Centre for Prevention and Treatment of Drug Use and Dependence. Psychiatric Hospital Skopje, Skopje, North Macedonia - [E-Mail: liljana.kitevaignjatova@ yahoo.com]

Mark ILGEN

University of Michigan, VA Ann Arbor Healthcare System - [E-Mail: marki@ umich.edu]

Marjetka JELENC

National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: Marjetka.

Jelenc@nijz.si]

Mariana JESUS

Department of Psychiatry, Coimbra Hospital and University Centre, Coimbra, Portugal, EU - [E-Mail: Mbsb.jesus@gmail.com]

Florence, Italy, October 25-27, 2018

- 14 -

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

Faculty Yifrah KAMINER

University of Connecticut School of Medicine, Connecticut, USA - [E-Mail: kaminer@uchc.edu]

Srinivas KANDRAKONDA

MaxCure Hospitals, Hi-tech City, , Hyderabad, India - [E-Mail: dr.srinivaskandrakonda@gmail.com]

Alexander KANTCHELOV

The Kantchelov Clinic, Sofia, Bulgaria, EU - [E-Mail: al.kantchelov@gmail.com]

Tatja KOSTNAPFEL

National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: tatja. kostnapfel@nijz.si]

Reinhard Michael KRAUSZ

University of British Columbia, Vancouver, BC, Canada, - [E-Mail: M.Krausz@ me.com]

Olga KUKHIANIDZE

Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia, Tbilisi, Georgia [E-Mail: olga.kukhianidze@gmail.com]

Lee KUN-HUA

Yuli Hospital, Ministry of Health and Welfare; The Department of Educational psychology and Counseling, National Tsing Hua University, Taiwan, Hsinchu, Taiwan - [E-Mail: kunhualee627@gmail.com]

Steven P. KURTZ

ARSH | Centre for Applied Research on Substance Use and Health Disparities, Abraham S. Fischler College of Education, School of Criminal Justice, Nova Southeastern University, Miami, FL, USA - [E-Mail: steven.kurtz@nova.edu]

Daniele LA BARBERA

University Hospital “Policlinico Paolo Giaccone”, Palermo, Italy, EU - [E-Mail: daniele.labarbera@unipa.it]

Arturo LERNER

Department of Dual Disorders, Lev-Hasharon Centre, Netanya, Israel - [E-Mail: alerner@lev-hasharon.co.il]

Shaul LEV-RAN

Lev Hasharon Medical Centre, Netanya, Israel - [E-Mail: shauli.levran@gmail. com]

Lars LIEN

Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Oslo, Norway - [E-Mail: lars.lien@medisin.uoi.no]

Mercedes LOVRECIC

National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: mercedes. lovrecic@nijz.si]

Marta LUCAS

Complejo Hospitalario Universitario de Albacete, Servicio de Salud Mental, Unidad de Hospitalización Breve,, Albacete, Spain, EU - [E-Mail: martamarta75@ hotmail.com]

Mario MAJ

Department of Psychiatry, University of Campania L. Vanvitelli, Naples, Italy, EU - [E-Mail: majmario@tin.it]

Corrado MANNI

School of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, EU - [E-Mail: corrado3@live.it]

Veronika MARCINKENE

Riga Stradins University, Riga, Latvia, EU - [E-Mail: ve.marcinkene@gmail.com]

Angelo G.I. MAREMMANI

Department of Psychiarty, Northern-West Tuscany Region Local Health Unit, Versilia Zone, Viareggio, Italy, EU - [E-Mail: angelogimaremmani@gmail.com]

Icro MAREMMANI

VP Dole Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: icro.maremmani@med.unipi.it]

Rodrigo MARIN-NAVARRETTE

National Institute of Psychiatry 'Ramon de la Fuente', Mexico City, Mexico [E-Mail: rmarin@inprf.gob.mx]

Julia E. MARQUEZ-ARRICO

University of Barcelona and Institute of Neuroscience, Barcelona, Spain, EU [E-Mail: aadan@ub.edu]

Florence, Italy, October 25-27, 2018

- 15 -

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

Faculty José MARTINEZ-RAGA Vera MARTINS

Hospital Universitario Doctor Peset & Universitat de Valencia, Valencia, Spain, EU - [E-Mail: martinez_josrag@gva.es] Dual Pathology Unit, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, EU - [E-Mail: vera_martins_83@hotmail.com]

David MEDVED

Norwegian Centre for Addiction Research, Oslo, Norway - [E-Mail: david. medved@medisin.uio.no]

Fernando MORA MÍNGUEZ

Hospital Universitario Infanta Leonor Madrid, Spain, EU - [E-Mail: fernmora@ gmail.com]

Ashley MULLER

Norwegian Centre for Addiction Research, University of Oslo, Norway - [E-Mail: ashley.muller@medisin.uio.no]

Filomena NETO

Community Mental Health Unit, Psychiatric Service, Centro Hospitalar Universitário de Coimbra, Portugal, Coimbra, Portugal, EU - [E-Mail: menaneto@ gmail.com]

Arjen NEVEN

Fivoor, Den Haag, Netherlands - [E-Mail: a.neven@fivoor.nl]

Ernst NOORDRAVEN

Centrum Dubbele Problematiek, Fivoor, Den Haag, Netherlands - [E-Mail: e.noordraven@fivoor.nl]

Lina OVIEDO

Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Barcelona, Spain, EU - [E-Mail: loviedo@parcdesalutmar.cat]

Matteo PACINI

Institute of Behavioural Sciences (IBS), Pisa, Italy, EU - [E-Mail: paciland@virgilio. it]

Alessandro PALLUCCHINI

School of Psychiatry, Department of Clinical and Experimental Psychiatry, University of Pisa, Pisa, Italy, EU - [E-Mail: pallucchini.a@gmail.com]

Myriam PAPERMAN

Hôpital Psychiatrique de Sainte Anne, Paris, France, EU - [E-Mail: myriampaperman@gmail.com]

Einat PELES

Adelson Clinic for Drug Abuse, Treatment & Research, Tel Aviv Medical Centre, and Sackler Faculty of Medicine, Tel-Aviv University, Israel - [E-Mail: einatp@ tlvmc.gov.il]

Viktorija PEREPJOLKINA

Riga Stradiņš University, Riga, Latvia, EU - [E-Mail: viktorijaperepjolkina@gmail. com]

Lola PERIS

Neuchâtel Psychiatry Centre, Neuchâtel, Switzerland - [E-Mail: dolores.perisdiaz@cnp.ch]

Giulio PERUGI

Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, Italy, EU - [E-Mail: giulio.perugi@med.unipi.it]

José Angel PRADO GARCIA

Centros de Integración Juvenil A.C. (CIJ), Mexico City, Mexico - [E-Mail: aprado@ cij.gob.mx]

Rocio Molina PRADO

Instituto de Adicciones. Madrid Salud City Hall, Madrid, Spain, EU - [E-Mail: romopra1@hotmail.com]

Gemma PRAT

University of Barcelona and Fundació Althaia, Manresa, Spain, EU - [E-Mail: gprat@althaia.cat, gprat@ub.edu]

Sharon RABINOVITZ

School of Criminology and The Unit for Excellence in Research & Study of Addiction (ERSA), The Centre for Rehabilitation Research, University of Haifa, Haifa, Israel - [E-Mail: sharonrs@univ.haifa.ac.il]

Ismail RAMMOUZ

Université Ibn Zohr, Faculté de Médicine, Agadir, Morocco - [E-Mail: ismailrammouzgmail.com]

Florence, Italy, October 25-27, 2018

- 16 -

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

Faculty Jeleana RISTIC-ILIC

Centre for Treatment of Drug Addiction, University Psychiatric Clinic Ljubljana, EU - [E-Mail: jelenaristicilic@gmail.com]

Ilario RITACCO

Roma, Italy, EU - [E-Mail: ritaccoilario@gmail.com]

María ROBLES-MARTÍNEZ

Instituto de Neuropsiquiatría y Adicciones (INAD). Parc de Salut Mar, Barcelona, Spain, - [E-Mail: correo@mariarobles.es]

Pasqualina ROCCO

Addiction Treatment Centre, Local Health Service n.2, Veneto, Castelfranco Veneto, Italy, EU - [E-Mail: pasqualina.rocco@aulss2.veneto.it]

Patricia ROMERO

Complejo Hospitalario Universitario de Albacete. Servicio de Salud Mental, Spain, EU, Albacete, Spain, EU - [E-Mail: patriciaromerorodenas@gmail.com]

Carlos RONCERO

Psychiatric Service, University of Salamanca Health Care Complex & Institute of Biomedicine of Salamanca, Psychiatric Departament, University of Salamanca, Salamanca, Spain, EU - [E-Mail: croncero@saludcastillayleon.es]

Paula ROSCA

Department for the Treatment of Substance Abuse, Ministry of Health, Hebrew University, , Jerusalem, Israel. - [E-Mail: Paola.Roska@MOH.GOV.IL]

Pedro RUIZ

Baylor College of Medicine, Houston, Texas, USA - [E-Mail: pruizmd@outlook. com]

Ana RUZ SÁNCHEZ

University Hospital Virgen de las Nieves, Granada, Spain, EU - [E-Mail: jflogrono@gmail.com]

Caroline SALOM

University of Queensland QLD, Brisbane, Australia - [E-Mail: c.salom@uq.edu.au]

Anat SASON

Adelson Clinic for Drug Abuse, Treatment & Research, Tel Aviv Medical Centre Tel Aviv, Israel - [E-Mail: anatsas@tlvmc.gov.il]

Rosa Blanca SAURAS QUETCUTI

Institut de Neuropsiquiatria i Addiccions (INAD); Parc de Salut Mar, IMIM (Hospital del Mar Medical Research Institute, Barcelona, Catalogna, Spain [E-Mail: rsauras@parcdesalutmar.cat]

Shaul SCHREIBER

Adelson Clinic for Drug Abuse, Treatment & Research, Tel Aviv Medical Centre, and Sackler Faculty of Medicine, Tel-Aviv University, Israel - [E-Mail: shaulsch@ tlvmc.gov.il]

Christian SCHUTZ

Institute of Mental Health, Department of Psychiatry, University of British Columbia, Vancouver, Canada, - [E-Mail: christian.schutz@ubc.ca]

Nusa SEGREC

Centre for Treatment of Drug Addiction, University Psychiatric Clinic Ljubljana, & Medical Faculty, University of Ljubljana, Slovenia, EU - [E-Mail: nusasegrec@ hotmail.com]

Liron SHRIKI-TAL

Ness-Ziona – Be’er Yaacov Mental Health Medical Centre, Ness-Ziona, Israel [E-Mail: aweller11@gmail.com]

Tania SILVA

Community Mental Health Unit, Psychiatric Service, Centro Hospitalar Universitário de Coimbra, Portugal, EU, Coimbra, Portugal, EU - [E-Mail: aniavdasilva.md@gmail.com]

Lorenzo SOMAINI

Addiction Medicine Clinic (SerT) Cossano, Biella, Italy, EU - [E-Mail: Lorenzo.

Somaini@aslbi.piemonte.it]

Giampaolo SPINNATO

UOC Addiction Unit, NHS Local Unit Palermo, Italy, EU - [E-Mail: sert.pa2@ asppalermo.org]

Robert G. STERN

Staten Island University Hospital, , Staten Island, NY, USA - [E-Mail: rgsternmd@ gmail.com]

Tsvetana STOYKOVA

The Kantchelov Clinic, Sofia, Bulgaria, EU - [E-Mail: cvetipost@gmail.com]

Florence, Italy, October 25-27, 2018

- 17 -

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Florence, Italy, October 25-27, 2018

Disorders|Congress

Faculty Nestor SZERMAN

University Hospital Gregorio Marañon, Madrid, Spain, - [E-Mail: nszermanb@ gmail.com]

Claudia TAGLIARINI

School of Psychiatry, University of Pisa, Pisa, Italy, EU - [E-Mail: claudiatagliarini8@gmail.com]

Lars TANUM

Norwegian Centre for Addiction Research, University of Oslo, Norway, Oslo, Norway - [E-Mail: Lars.Tanum@ahus.no]

Rok TAVCAR

University Psychiatric Clinic, Ljubljana, Slovenia, EU - [E-Mail: rok.tavcar@psihklinika.si]

Marta TORRENS

Department of Psychiatry, Universitat Autònoma de Barcelona, Spain - [E-Mail: mtorrens@parcdesalutmar.cat]

Albrecht ULMER

Addiction Practitioner, Stuttgard, Germany, EU - [E-Mail: albrecht.ulmer@gmx. de]

Roger D. WEISS

Harvard Medical School, Boston, MA, USA; McLean Hospital,, Belmont, MA, USA - [E-Mail: rweiss@mclean.harvard.edu]

Aviva WOLF

Ness-Ziona–Be’er Yaacov Mental Health Care Centre, Ness Ziona, - [E-Mail: shirleykeisar@hotmail.com]

Daniele ZULLINO

Neuroscience Centre, Université de Genève, Geneve, Switzerland - [E-Mail: Daniele.Zullino@hcuge.ch, h.rahioui@ch-sainte-anne.fr]

Florence, Italy, October 25-27, 2018

- 18 -

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8 World

Associationon

on

Dual

Disorders|Congress

“The 2nd World Association of Dual Disorders (WADD) Congress, Florence, Italy, 25/10/2018-27/10/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 20 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”

World

Associationon

on

Dual

Disorders|Congress

WA D D F l o re n c e 2 0 1 8

Platinum sponsor

Bronze sponsor

WADD 2nd World Congress Thursday, 25 October 2018, 12:00 - 13:30 Convitto della Calza, Florence, Tuscany, ITALY, EU Plenary Room

OPIOID USE DISORDER IN EUROPE: DEFINING THE ROAD AHEAD Chair: Icro Maremmani1 (Pisa, Italy, EU) Faculty: Maurice Dematteis2 (Grenoble, France, EU), Lorenzo Somaini3 (Biella, Italy, EU), Carlos Roncero4 (Salamanca,Spain, EU)

Time

Presentation title

Speaker

12:00–12:10

Paving the way: Welcome and introductions To illustrate historical context of past treatment management and the impact of having dedicated OST programmes

Icro Maremmani

12:10–12:30

Update on drug-related mortality in Europe

Carlos Roncero

Drug-related deaths (DRDs) continue to be a major public health concern in Europe5 Deaths related to opioid overdose remain high Brief overview of multiple factors contribute to continued high rates of opioid-related deaths 12:30–12:50

Driving continued improvement in OUD: evidence and considerations

Lorenzo Somaini

Current treatment practices for OUD may be suboptimal from physician and patient perspective 12:50–13:10

Towards a consensus-based approach to the management of OUD

Maurice Dematteis

The variation in treatment practices across Europe necessitated the devel-opment of consensus recommendations5 13:10–13:30

Faculty discussion

Led by Icro Maremmani

1. Santa Chiara University Hospital, 2nd Psychiatric Unit, University of Pisa, Italy, Pisa, Italy, EU - [E-Mail: icro.maremmani@med. unipi.it] 2. CHU Grenoble-Alpes, Grenoble, France, EU; INSERM UMR 987, Boulogne Billancourt, France; Hospital Cochin, Paris, France, EU -, Grenoble, France, EU - [E-Mail: MDematties@chu-grenoble.fr] 3. NHS, Addiction Medicine Unit (SerT) Cossano, Biella, Italy, EU - [E-Mail: Lorenzo.Somaini@aslbi.piemonte.it] 4. Psychiatric Service, University of Salamanca Health Care Complex & Institute of Biomedicine of Salamanca, Psychiatric Departa-ment, University of Salamanca, Salamanca, Spain, EU - [E-Mail: croncero@saludcastillayleon.es] 5. EMCDDA European Drug Report. 2017